Literature DB >> 9878989

Practical guide for the treatment of leishmaniasis.

R N Davidson1.   

Abstract

This article summarises the clinical features of visceral, cutaneous and mucocutaneous leishmaniasis, and leishmaniasis in HIV-coinfected patients. The characteristics and clinical use of pentavalent antimonials and the traditional drugs used in all forms of leishmaniasis are described. There have been important developments in therapy, such as aminosidine (paromomycin) conventional amphotericin B and lipid-associated amphotericin B. In most cases of leishmaniasis there is a range of treatment options which is determined by the geographical and clinical features. This review is intended to assist the clinician in choosing treatment and in using unfamiliar drugs with safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9878989     DOI: 10.2165/00003495-199856060-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  36 in total

1.  Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil.

Authors:  R A Neal; J van Bueren; N G McCoy; M Iwobi
Journal:  Trans R Soc Trop Med Hyg       Date:  1989 Mar-Apr       Impact factor: 2.184

2.  Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis.

Authors:  A Llanos-Cuentas; J Echevarría; M Cruz; A La Rosa; P Campos; M Campos; E Franke; J Berman; F Modabber; J Marr
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

3.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

4.  Mucosal leishmaniasis unresponsive to glucantime therapy successfully treated with AmBisome.

Authors:  R Nonata; R Sampaio; P D Marsden
Journal:  Trans R Soc Trop Med Hyg       Date:  1997 Jan-Feb       Impact factor: 2.184

5.  Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.

Authors:  J D Chulay; L Fleckenstein; D H Smith
Journal:  Trans R Soc Trop Med Hyg       Date:  1988       Impact factor: 2.184

Review 6.  Clinical use of liposomal and lipid-complexed amphotericin B.

Authors:  S de Marie; R Janknegt; I A Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  1994-05       Impact factor: 5.790

7.  Leishmaniasis of the tongue treated with liposomal amphotericin B.

Authors:  G G Baily; M A Pitt; A Curry; N Y Haboubi; J R Tuffin; B K Mandal
Journal:  J Infect       Date:  1994-05       Impact factor: 6.072

8.  Observations on the effect of verapamil with sodium stibogluconate in kala azar.

Authors:  C P Thakur; M Kumar
Journal:  Trop Geogr Med       Date:  1992-01

9.  Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.

Authors:  M Gramiccia; L Gradoni; S Orsini
Journal:  Ann Trop Med Parasitol       Date:  1992-12

10.  Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala.

Authors:  T R Navin; B A Arana; F E Arana; J D Berman; J F Chajón
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

View more
  20 in total

1.  Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.

Authors:  A H Groll; D Mickiene; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient.

Authors:  Patricia Barragán; Rogelio López-Velez; Montserrat Olmo; Daniel Podzamczer
Journal:  Am J Trop Med Hyg       Date:  2010-07       Impact factor: 2.345

3.  Miltefosine (Impavido): the first oral treatment against leishmaniasis.

Authors:  H Sindermann; S L Croft; K R Engel; W Bommer; H J Eibl; C Unger; J Engel
Journal:  Med Microbiol Immunol       Date:  2003-09-26       Impact factor: 3.402

Review 4.  Amphotericin B lipid complex: in visceral leishmaniasis.

Authors:  David R Goldsmith; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  [Cutaneous leishmaniasis].

Authors:  C D Enk; K Gardlo; M Hochberg; A Ingber; T Ruzicka
Journal:  Hautarzt       Date:  2003-04-18       Impact factor: 0.751

Review 6.  The relationship between leishmaniasis and AIDS: the second 10 years.

Authors:  Jorge Alvar; Pilar Aparicio; Abraham Aseffa; Margriet Den Boer; Carmen Cañavate; Jean-Pierre Dedet; Luigi Gradoni; Rachel Ter Horst; Rogelio López-Vélez; Javier Moreno
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

7.  [Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality].

Authors:  K Gardlo; S Hanneken; T Ruzicka; N J Neumann
Journal:  Hautarzt       Date:  2004-04       Impact factor: 0.751

8.  In vivo efficacy of gum obtained pistacia atlantica in experimental treatment of cutaneous leishmaniasis.

Authors:  M Taran; M Mohebali; J Esmaeli
Journal:  Iran J Public Health       Date:  2010-03-31       Impact factor: 1.429

Review 9.  Neglected tropical diseases: survey and geometry of randomised evidence.

Authors:  Shanthi Kappagoda; John P A Ioannidis
Journal:  BMJ       Date:  2012-10-22

10.  Visceral leishmaniasis treatment, Italy.

Authors:  Luigi Gradoni; Marina Gramiccia; Aldo Scalone
Journal:  Emerg Infect Dis       Date:  2003-12       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.